...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatology >Digital ulcers: overt vascular disease in systemic sclerosis.
【24h】

Digital ulcers: overt vascular disease in systemic sclerosis.

机译：数字溃疡：系统性硬化中的明显血管疾病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

RP is an almost universal manifestation of SSc, with 95% of all patients being affected, and resulting in digital ulcers (DUs) in approximately 30% of the patients each year. DUs are a major clinical problem, being associated with substantial morbidity (reduced quality of life, pain, disability and disfigurement) that can escalate to gangrene and amputation. Ideally, the treatment of DUs would improve tissue integrity and viability, promote ulcer healing and reduce the formation of new ulcers. Treatments that have shown potential include calcium channel blockers, prostacyclin analogues and endothelin receptor antagonists. However, until recently, management was based on empirical experience. The recent approval (in Europe) of the dual endothelin receptor antagonist, bosentan, to reduce the number of new DUs in patients with SSc and ongoing DU disease, means that there is now an approved therapy--and new hope--for the treatment of DUs in these severely afflicted patients.
机译：RP几乎是SSc的普遍表现，所有患者中有95％受到感染，每年约有30％的患者会导致数位溃疡（DUs）。 DUs是一个主要的临床问题，与可能升级为坏疽和截肢的大量发病率（生活质量下降，疼痛，残疾和毁容）有关。理想地，DU的治疗将改善组织完整性和生存力，促进溃疡愈合并减少新溃疡的形成。已显示出潜力的治疗方法包括钙通道阻滞剂，前列环素类似物和内皮素受体拮抗剂。但是，直到最近，管理还是基于经验。最近在欧洲批准了双重内皮素受体拮抗剂波生坦，以减少SSc和进行中的DU病患者中新DU的数量，这意味着该疗法现在已经获得批准，并且有了新的希望这些严重折磨患者中的DUs百分比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号